By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
No open-market selling at Filana Therapeutics, Inc. in the past year, which is unusual. Instead one officers and board members purchased about $356,000 worth of FLNA.
Biggest single buyer: Barry Richard, CEO, with roughly $186,000. That includes C-suite money, which tends to get the most attention.
Zooming out by quarter: Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters. On the institutional side, 85 funds reported holding FLNA at the end of Q2 2026, and more funds sold than bought.
Are insiders buying or selling FLNA stock?
In the last 12 months Filana Therapeutics, Inc. insiders made open-market purchases worth about $356,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in FLNA?
The most recent open-market insider trade in FLNA was filed on 2026-10-01.
How many institutions own FLNA?
85 investment managers reported holding FLNA in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded FLNA?
No congressional trades in FLNA were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).